Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL518144 | 0.98 | TDP1 (0.34) | TDP1CA2TSHRALDH1A1NAMPT | |
| SCHEMBL30179205 | 0.82 | TSHR (0.42) | CA2TSHRALDH1A1HSD17B10NAMPT | |
| SCHEMBL28565203 | 0.82 | CA2 (0.35) | TDP1CA2TSHRALDH1A1NAMPT | |
| SCHEMBL8390474 | 0.82 | CA2 (0.35) | TDP1CA2TSHRALDH1A1NAMPT | |
| SCHEMBL5049754 | 0.82 | TSHR (0.42) | CA2TSHRALDH1A1HSD17B10NAMPT | |
| SCHEMBL16917910 | 0.82 | TSHR (0.42) | CA2TSHRALDH1A1HSD17B10NAMPT | |
| SCHEMBL15360069 | 0.82 | TSHR (0.42) | CA2TSHRALDH1A1HSD17B10NAMPT | |
| SCHEMBL31672720 | 0.82 | TSHR (0.42) | CA2TSHRALDH1A1HSD17B10NAMPT | |
| SCHEMBL7043209 | 0.81 | CA2 (0.38) | CA2TSHRALDH1A1TP53HIF1A | |
| SCHEMBL4405371 | 0.79 | ALDH1A1 (0.35) | TDP1CA2TSHRALDH1A1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427186-B1 | DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GES M B H (AT) | 2022-01-12 | — | — | EP | disclosed |
| US-8354433-B2 | Anti-inflammatory agents as virostatic compounds | 4SC AG (DE) | 2013-01-15 | — | — | US | disclosed |
| EP-2427186-A2 | DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2362771-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2011-09-07 | — | — | EP | disclosed |
| EP-2283898-A1 | Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2011-02-16 | — | — | EP | disclosed |
| WO-2010128050-A2 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-11 | — | — | WO | disclosed |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| WO-2010052027-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2010-05-14 | — | — | WO | disclosed |
| EP-1392642-B1 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2009-12-09 | — | — | EP | disclosed |
| EP-1578741-A1 | AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| EP-1541198-A1 | Cycloalkyl compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040192758-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2004-09-30 | — | — | US | disclosed |
| US-20040176458-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004056797-A1 | AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056746-A1 | CYCLOALKENE DICARBOXYLIC ACID COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |
| EP-1392642-A2 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-03-03 | — | — | EP | disclosed |
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2003-10-30 | — | — | US | disclosed |
| WO-2003006425-A2 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2003-01-23 | — | — | WO | disclosed |
| WO-2003006424-A1 | NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203951-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | DHODH, DLD, GCDH | TDP1 1341/4885CA2 3054/4885TSHR 4756/4885 |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | HLA-DRB1, IL2, SSB | TDP1 3217/4885CA2 950/4885TSHR 1542/4885 |
| US-20040176458-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | MSR1, PPARG, PPARA | TDP1 3902/4885CA2 1881/4885TSHR 1037/4885 |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | TNF, MIF, IL1B | TDP1 2616/4885CA2 1839/4885TSHR 4652/4885 |
| US-20040192758-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | PPARG, PPARD, PPARA | TDP1 2938/4885CA2 3508/4885TSHR 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.